comparemela.com

Latest Breaking News On - Breast cancer congress - Page 2 : comparemela.com

Adding Tecentriq to Chemo Did Not Boost TNBC Survival

The addition of Tecentriq to chemotherapy did not improve overall survival in patients with relapsed triple-negative breast cancer.

Singapore
Breast-cancer-congress
National-cancer-center-singapore
Adding-tecentriq

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Berlin
Germany
San-francisco
California
United-states
Department-of-medicine
Helen-diller-comprehensive-cancer-center
Cancer-infusion-services
University-of-california
Breast-cancer-congress
Breast-oncology

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Barcelona
Comunidad-autonoma-de-cataluna
Spain
Hebron
Israel-general
Israel
Daiichi-sankyo-astrazeneca
Mafalda-oliveira
Pfizer
Genentech
Breast-cancer-congress
Novartis

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

James-cayne
Komal-jhaveri
Early-drug-development-service
Endocrine-therapy-research-program
Breast-cancer-congress
Cancer-congress
James-cayne-chair
Junior-faculty
Memorial-sloan-kettering-cancer-center

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

London
City-of
United-kingdom
Peter-schmid
Astrazeneca
Pfizer
Barts-cancer-institute-of-queen-mary-university
Novartis
Breast-cancer-congress
Boehringer-ingelheim
Amgen
Cancer-congress

vimarsana © 2020. All Rights Reserved.